<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id><journal-id journal-id-type="publisher-id">jbc</journal-id><journal-title>The Journal of Biological Chemistry</journal-title><issn pub-type="ppub">0021-9258</issn><issn pub-type="epub">1083-351X</issn><publisher><publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">23326</article-id><article-id pub-id-type="doi">10.1074/jbc.M801706200</article-id><article-id pub-id-type="pmid">18511415</article-id><article-categories><subj-group subj-group-type="heading"><subject>Protein Structure and Folding</subject></subj-group></article-categories><title-group><article-title>Structural Consequences of Nucleophosmin Mutations in Acute Myeloid Leukemia<xref ref-type="fn" rid="fn1">*</xref></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Grummitt</surname><given-names>Charles G.</given-names></name><xref ref-type="aff" rid="N0x1cc07a0N0x1e82780">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Townsley</surname><given-names>Fiona M.</given-names></name><xref ref-type="aff" rid="N0x1cc07a0N0x1e82780">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Christopher M.</given-names></name><xref ref-type="aff" rid="N0x1cc07a0N0x1e82780">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Warren</surname><given-names>Alan J.</given-names></name><xref ref-type="aff" rid="N0x1cc07a0N0x1e82780">&#x000a7;</xref><xref ref-type="aff" rid="N0x1cc07a0N0x1e82780">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Bycroft</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="N0x1cc07a0N0x1e82780">&#x02021;</xref><xref ref-type="corresp" rid="cor1">1</xref></contrib></contrib-group><aff id="N0x1cc07a0N0x1e82780"><label>&#x02021;</label>Medical Research Council Centre for Protein Engineering and <label>&#x000a7;</label>Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH and the <label>&#x000b6;</label>Department of Haematology, University of Cambridge, Hills Road, Cambridge CB2 2XY, United Kingdom</aff><author-notes><fn id="cor1"><label>1</label><p> To whom correspondence should be addressed. Tel.: 44-1223-402129; Fax: 44-1223-402140; E-mail: <email>mxb@mrc-lmb.cam.ac.uk</email>. </p></fn></author-notes><pub-date pub-type="ppub"><day>22</day><month>8</month><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>8</month><year>2008</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the copyright element. --><volume>283</volume><issue>34</issue><fpage>23326</fpage><lpage>23332</lpage><history><date date-type="received"><day>3</day><month>3</month><year>2008</year></date><date date-type="rev-recd"><day>23</day><month>5</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008, The American Society for Biochemistry and Molecular Biology, Inc.</copyright-statement><license license-type="open-access"><p><italic>Author's Choice</italic></p><p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution Non-Commercial License</ext-link> applies to Author Choice Articles</p></license></permissions><self-uri xlink:title="pdf" xlink:href="zbc03408023326.pdf"/><abstract><p>Mutations affecting NPM1 (nucleophosmin) are the most common genetic lesions found in acute myeloid leukemia (AML). NPM1 is one of the most abundant proteins found in the nucleolus and has links to the MDM2/p53 tumor suppressor pathway. A distinctive feature of NPM1 mutants in AML is their aberrant localization to the cytoplasm of leukemic cells. This mutant phenotype is the result of the substitution of several C-terminal residues, including one or two conserved tryptophan residues, with a leucine-rich nuclear export signal. The exact molecular mechanism underlying the loss of nucleolar retention, and the role of the tryptophans, remains unknown. In this study we have determined the structure of an independently folded globular domain in the C terminus of NPM1 using NMR spectroscopy, and we report that the conserved tryptophans are critical for structure. This domain is necessary for the nucleolar targeting of NPM1 and is disrupted by mutations in AML with cytoplasmic NPM1. Furthermore, we identify conserved surface-exposed lysine residues that are functionally rather than structurally important for nucleolar localization. This study provides new focus for efforts to understand the pathogenesis of AML with cytoplasmic NPM1 and may be used to aid the design of small molecules that target the C-terminal domain of NPM1 to act as novel anti-proliferative and anti-leukemia therapeutics.</p></abstract></article-meta><notes><fn-group><fn><p><italic>Author's Choice</italic>&#x02014;Final version full access.</p></fn><fn><p><italic>The atomic coordinates and structure factors (code 2vxd) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/">http://www.rcsb.org/</ext-link>).</italic></p></fn><fn id="fn1"><label>*</label><p>This work was supported in part by the <grant-sponsor>Leukaemia Research Fund</grant-sponsor>. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked &#x0201c;<italic>advertisement</italic>&#x0201d; in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn></fn-group></notes></front><body><p>The gene encoding nucleophosmin (<italic>NPM1</italic>) is mutated in 50-60% of normal karotype adult acute myeloid leukemia (AML),<xref ref-type="fn" rid="fn2">2</xref> making <italic>NPM1</italic> mutations the most common genetic lesions identified to date in <italic>de novo</italic> AML. NPM1 (nucleophosmin, also known as B23 or numatrin) is a ubiquitously expressed protein that belongs to the nucleoplasmin family of nuclear chaperones. Found predominantly in the nucleolus, NPM1 is used as a marker for the granular component (<xref ref-type="bibr" rid="ref1">1</xref>-<xref ref-type="bibr" rid="ref3">3</xref>) (the site of pre-ribosomal subunit assembly (<xref ref-type="bibr" rid="ref4">4</xref>)). NPM1 rapidly shuttles between the nucleoplasm and the cytoplasm (<xref ref-type="bibr" rid="ref5">5</xref>-<xref ref-type="bibr" rid="ref7">7</xref>) serving as a chaperone for both nucleic acids and proteins (<xref ref-type="bibr" rid="ref8">8</xref>-<xref ref-type="bibr" rid="ref11">11</xref>). NPM1 is essential for embryonic development (<xref ref-type="bibr" rid="ref12">12</xref>) and appears to modulate diverse molecular functions, including ribosome biogenesis (<xref ref-type="bibr" rid="ref13">13</xref>-<xref ref-type="bibr" rid="ref16">16</xref>) and genomic stability (<xref ref-type="bibr" rid="ref12">12</xref>). NPM1 is overexpressed in a number of solid tumors (<xref ref-type="bibr" rid="ref17">17</xref>), is linked to the p53/MDM2 pathway via the tumor suppressor ARF (<xref ref-type="bibr" rid="ref18">18</xref>-<xref ref-type="bibr" rid="ref22">22</xref>), and is a transcriptional target of Myc (<xref ref-type="bibr" rid="ref23">23</xref>, <xref ref-type="bibr" rid="ref24">24</xref>).</p><p>A distinctive feature of NPM1 mutants in AML is their aberrant localization to the cytoplasm of leukemic cells (NPMc+ AML) (<xref ref-type="bibr" rid="ref25">25</xref>). Two consequences of mutation-related sequence changes at the C terminus of NPM1 promote aberrant cytoplasmic localization of mutant NPM1 proteins in NPMc+ AML. First, generation of an additional leucine-rich nuclear export motif reinforces Crm1 (XpoI)-dependent nuclear export of NPM1 leukemic mutants (<xref ref-type="bibr" rid="ref26">26</xref>). Second, there is loss of tryptophan residues Trp<sup>288</sup> and Trp<sup>290</sup> (or Trp<sup>290</sup> alone) that determine NPM1 nucleolar localization (<xref ref-type="bibr" rid="ref25">25</xref>, <xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref28">28</xref>). However, the precise molecular mechanisms that regulate the steady state distribution of NPM1 are unknown. In this study, we tested the hypothesis that NPM1 tryptophans Trp<sup>288</sup> and Trp<sup>290</sup> are critical structural components of an independently folded domain that is essential for nucleolar targeting of NPM1. These studies provide a structural basis for understanding the mechanisms underlying NPMc+ AML.</p><sec sec-type="methods"><title>EXPERIMENTAL PROCEDURES</title><p><italic>Reagents</italic>&#x02014;Mutants NPM1 W288A/W290A and NPM1 F268A/F276A were made by site-directed mutagenesis and mutants A and E by PCR using appropriate primers. NPM1 C-terminal domain variants, with the exception of mutant A, were cloned into a modified pRSETA vector (Invitrogen) expressing the protein fused to a tobacco etch virus protease-cleavable His<sub>6</sub>-tagged lipoyl domain from <italic>Bacillus stearothermophilus</italic>. Proteins were expressed in <italic>Escherichia coli</italic> strain C41 and purified using Ni<sup>2+</sup>-chelating affinity chromatography. Fusion proteins were cleaved by tobacco etch virus protease digestion and removed in a second affinity step before concentration and final purification by size exclusion chromatography on a GF30 column (Amersham Biosciences). For isotopic labeling, K-MOPS minimal media containing <sup>15</sup>NH<sub>4</sub>Cl and/or [<sup>13</sup>C]glucose was used. Mutant A C-terminal domain was made using a Liberty CEM microwave peptide synthesizer (Matthews, NC) and standard Fmoc (<italic>N</italic>-(9-fluorenyl)methoxycarbonyl) /t-butyl chemistry and purified by reverse-phase high pressure liquid chromatography. All C-terminal constructs have an additional two glycine residues at the N terminus as a result of the cloning and purification strategy; residue numbering is in context of the full-length protein and omits these glycines.</p><p><fig position="float" id="fig1"><label>FIGURE 1.</label><caption><p><bold>Solution structure of the C-terminal domain of nucleophosmin.</bold><italic>A,</italic> overlay of the backbone atoms of the 20 lowest energy structures in stereo. <italic>B,</italic> schematic representation of the lowest energy structure colored <italic>blue</italic> to <italic>red</italic> from the N to C terminus (same orientation as in <italic>A</italic>). Prepared using the program PyMOL (<xref ref-type="bibr" rid="ref53">53</xref>).</p></caption><graphic xlink:href="zbc0330845150001"></graphic></fig></p><p>SDS-PAGE and electrospray mass spectrometry were used to confirm proteins were of the expected mass and to assess their purity. Protein concentration was determined spectroscopically using a Varian Cary 500 spectrometer (Varian, NC), and extinction coefficients were calculated for 280 nm (<xref ref-type="bibr" rid="ref29">29</xref>, <xref ref-type="bibr" rid="ref30">30</xref>). All reagents were purchased from Sigma and were Anal-R grade or higher, except for isotopically enriched reagents, which were purchased from Cambridge Isotopes (Cambridge, UK).</p><p><italic>Spectroscopic Measurements</italic>&#x02014;The NMR spectra were recorded on Bruker Advance-800, Advance-II<sup>+</sup> 700, and Advance-600 spectrometers. Two-dimensional NOESY, TOCSY, DQF-COSY, <sup>15</sup>N-HSQC, constant time <sup>13</sup>C-HSQC and <sup>13</sup>C-TOCSY were recorded at 298 K. The mixing times chosen were 80 ms for TOCSY and 120 ms for NOESY. Spectra were referenced relative to external sodium 2,2-dimethyl-2-silapentane-5-sulfonate for signals of proton and carbon, or liquid ammonium for that of nitrogen. Approximately half the Hb resonances were assigned stereospecifically using a combination of HNHB and DQF-COSY spectra. All the Val(H&#x003b3;) and Leu(H&#x003b4;) resonances were assigned stereospecifically using a 10% <sup>13</sup>C-labeled sample of NPM1 C-terminal domain (<xref ref-type="bibr" rid="ref31">31</xref>). All the NMR spectra were analyzed with Sparky (<xref ref-type="bibr" rid="ref32">32</xref>).</p><p>All samples used for structure determination were 1.2 m<sc>m</sc> and prepared in 10 m<sc>m</sc> MES, pH 6.5, 150 m<sc>m</sc> NaCl, 5 m<sc>m</sc> dithiothreitol, 0.02% sodium azide, and 5% D<sub>2</sub>O (homonuclear samples were in a deuterated version of this buffer). For hydrogen exchange experiments, the <sup>15</sup>N-labeled NPM1 C-terminal domain was exchanged into NMR buffer containing 100% D<sub>2</sub>O using a NAP-10 column (Amersham Biosciences), and a series of <sup>1</sup>H-<sup>15</sup>N-FHSQC spectra (<xref ref-type="bibr" rid="ref33">33</xref>) were recorded over the course of 6 h. All one-dimensional <sup>1</sup>H NMR experiments were conducted in biophysics buffer (10 m<sc>m</sc> KP<sub>i</sub>, pH 6.5, 150 m<sc>m</sc> NaCl, 5% D<sub>2</sub>O).</p><p><italic>Structure Determination</italic>&#x02014;The distance constraints derived from the NOESY spectra were classified into four categories corresponding to inter-proton distance constraints of 1.8-2.8, 1.8-3.5, 1.8-4.75, and 1.8-6.0 &#x000c5;, respectively. Hydrogen bond constraints of 1.8-2.1 &#x000c5; were imposed on the distance between the hydrogen and the acceptor oxygen, whereas another constraint of 2.7-3.1 &#x000c5; was imposed on the distance between the donor nitrogen and the acceptor oxygen. Torsion angle constraints were obtained from stereospecific assignment of residue side chains and incorporated in the structure calculation, along with the backbone &#x003d5; and &#x003c8; angle constraints determined with the program TALOS (<xref ref-type="bibr" rid="ref34">34</xref>). The structures were calculated using a standard torsion angle dynamics simulated annealing protocol with the program CNS (<xref ref-type="bibr" rid="ref35">35</xref>). 150 structures were accepted out of 150, produced with no distance violations greater than 0.25 &#x000c5;, and no angle violations greater than 5&#x000b0;. Of these the 20 lowest energy structures were selected for presentation and statistical representation.</p><p><italic>Circular Dichroism</italic>&#x02014;CD spectra of NPM1 were recorded between 260 and 190 nm at 30-60 &#x003bc;<sc>m</sc> in the biophysics buffer using a Jasco-J815 spectropolarimeter (Jasco Inc., Easton, MD) and a 1-mm path length cuvette. The base line due to the buffer only was recorded and subtracted prior to normalizing the data for concentration. Thermal denaturation was followed at 222 nm with heating from 277 to 371 K at a rate of 1 K&#x000b7;min<sup>-1</sup>. Data were fit to a standard two-state denaturation as described elsewhere (<xref ref-type="bibr" rid="ref36">36</xref>).</p><p><italic>Immunofluorescence</italic>&#x02014;Full-length NPM1 variants were cloned into the mammalian expression vector pEGFP-C1 (BD Biosciences). NPM1 variants were thus expressed <italic>in vivo</italic> with an N-terminal enhanced green fluorescent protein (eGFP) tag.</p><p>NIH-3T3 murine fibroblasts were grown in Dulbecco's modified Eagle's medium GlutaMAX&#x02122; (Invitrogen) supplemented with 10% fetal calf serum. A day before transfection a confluent flask of cells was subcultured at a 1:8 dilution in 6-well plates containing glass coverslips. Transfection was performed using Lipofectamine 2000 (Invitrogen) as per the manufacturer's instructions. After 24 h coverslips were removed, washed with PBS, and fixed in 4% paraformaldehyde for 20 min. Cells were permeabilized with PBS + 0.1% Triton X-100 prior to blocking for 30 min with 20% fetal calf serum, 0.5% Tween 20 in PBS (FATS). Cells were stained with mouse anti-fibrillarin (ab4566, AbCam, UK) at 1:500 in FATS for 1 h. After three washes with PBS + 0.1% Triton X-100, the cells were incubated in the dark for 1 h with Alexa Fluor&#x02122; 594-conjugated goat anti-mouse antibody (Molecular Probes, Leiden, Netherlands) at 1:200 in FATS. The coverslips were dried in air and mounted using Fluoromount-G&#x02122; (Southern Biotech, Birmingham, AL). Images were collected using an MRC-2000 plus confocal apparatus (Bio-Rad) mounted on a Nikon eclipse E800 microscope using the &#x000d7;60 oil objective lens.</p></sec><sec><title>RESULTS</title><p><italic>The Structure of the NPM1 C-terminal Domain</italic>&#x02014;Manual inspection of the sequence of NPM1, with assistance from the secondary structure prediction tool Jpred (<xref ref-type="bibr" rid="ref37">37</xref>), indicated the potential for three short helices separated by short loops within the last 50 residues. This potential domain is separated from the N-terminal oligomerization domain by an &#x0223c;120-residue acid-rich region that is predicted to be disordered. The DNA sequence corresponding to residues 243-294 of NPM1 was cloned and overexpressed in <italic>E. coli</italic>. Inspection by SDS-PAGE and electrospray-mass spectrometry following purification identified a pure protein of the expected mass. Both one-dimensional <sup>1</sup>H NMR and <sup>15</sup>N-HSQC experiments produced well dispersed spectra that are characteristic of a folded protein (<xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>).</p><p>The NMR spectra of residues Ser<sup>243</sup> to Leu<sup>294</sup> of NPM1 were assigned, and the solution structure was determined using standard techniques (<xref ref-type="bibr" rid="ref38">38</xref>, <xref ref-type="bibr" rid="ref39">39</xref>). Residues 244-294 adopt a well defined tertiary structure with a root mean square deviation of 0.4 &#x000c5; for backbone atoms (<xref rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>). Experimental restraints and structural statistics for the 20 accepted lowest energy structures are summarized in <xref ref-type="table" rid="tbl1">Table 1</xref>. The coordinates for the structure are available from the Protein Data Bank (entry code 2vxd).</p><p><table-wrap position="float" id="tbl1"><label>TABLE 1</label><caption><p><bold>Summary of conformational constraints and statistics for the 20 lowest energy accepted structures of <italic>C</italic>-terminal domain of nucleophosmin</bold></p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="1" rowspan="1" align="left" valign="bottom"><bold>Structural constraints</bold></td><td colspan="1" rowspan="1" align="center" valign="bottom"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Intra-residue </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 823 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Sequential </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 196 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Medium range (2 &#x02265;&#x0007c;<italic>i</italic> - <italic>j</italic>&#x0007c; &#x02265; 4) </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 219 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Long range (&#x0007c;<italic>i</italic> - <italic>j</italic>&#x0007c; &#x0003e; 4) </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 118 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"><italic>X</italic>1 angle constraints </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 15 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> ALOS constraints </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 77 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Hydrogen bond constraints </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 50 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Total </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 1498 </td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="bottom"><bold>Statistics for accepted structures</bold></td><td colspan="1" rowspan="1" align="center" valign="bottom"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Statistics parameter (&#x000b1;S.D.) </td><td colspan="1" rowspan="1" align="center" valign="bottom"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> r.m.s.d.<xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref> for distance constraints </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 0.0084 &#x000b1; 0.0003 &#x000c5; </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> r.m.s.d. for dihedral constraints </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 0.345 &#x000b1; 0.029&#x000b0; </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Mean CNS energy term (kcal&#x000b7;mol<sup>&#x02212;1</sup> &#x000b1; S.D.) </td><td colspan="1" rowspan="1" align="center" valign="bottom"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"><italic>E</italic> (overall) </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 50.3 &#x000b1; 4.2 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"><italic>E</italic> (van der Waals) </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 15.8 &#x000b1; 2.9 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"><italic>E</italic> (NOE and hydrogen bond constraints) </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 3.1 &#x000b1; .2 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"><italic>E</italic> (<italic>X</italic>-1 dihedral and TALOS constraints) </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 0.56 &#x000b1; 0.1 </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> r.m.s.d. from the ideal geometry (&#x000b1;S.D.) </td><td colspan="1" rowspan="1" align="center" valign="bottom"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Bond lengths </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 0.0015 &#x000b1; 0.00009 &#x000c5; </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Bond angles </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 0.32 &#x000b1; 0.007&#x000b0; </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Improper angles </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 0.24 &#x000b1; 0.013&#x000b0; </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Average atomic r.m.s.d. from the mean structure (&#x000b1; S.D.) </td><td colspan="1" rowspan="1" align="center" valign="bottom"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Residues 3-54 (N, C-&#x003b1;, C atoms) </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 0.40 &#x000b1; 0.07 &#x000c5; </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Residues 3-54 (all heavy atoms) </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 0.94 &#x000b1; 0.08 &#x000c5; </td></tr></tbody><tbody><tr><td colspan="1" rowspan="1" align="left" valign="bottom"><bold>Structural quality</bold></td><td colspan="1" rowspan="1" align="center" valign="bottom"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Residues in most favored region of Ramachandran plot </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 94.1% </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Residues in additional allowed region of Ramachandran plot </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 5.2% </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom"> Residues in disallowed region of Ramachandran plot </td><td colspan="1" rowspan="1" align="center" valign="bottom"> 0.3% </td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p>r.m.s.d. means root mean square deviation; NOE means nuclear Overhauser effect.</p></fn></table-wrap-foot></table-wrap></p><p>The C-terminal domain of NPM1 forms a well defined right-handed 3-helix bundle (<xref rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>). Helix 1 is formed of residues Val<sup>244</sup> to Glu<sup>256</sup>, with Lys<sup>257</sup> and Gly<sup>258</sup> then forming an H-bonded turn into the first loop Gly<sup>259</sup>-Pro<sup>264</sup>. Helix 2 runs from Glu<sup>265</sup> to Phe<sup>276</sup> until the second loop of Arg<sup>277</sup>-Asp<sup>280</sup>, and helix 3 is composed of residues Gln<sup>281</sup> to Lys<sup>292</sup>. The core of the protein is formed largely by aromatic residues (Tyr<sup>271</sup>, Phe<sup>268</sup>, Phe<sup>276</sup>, Trp<sup>288</sup>, and Trp<sup>290</sup>) with further contribution from residues Met<sup>251</sup>, Ile<sup>255</sup>, Leu<sup>261</sup>, Val<sup>272</sup>, and Leu<sup>287</sup>. Sequence alignment of homologous proteins (<xref rid="fig2" ref-type="fig">Fig. 2<italic>D</italic></xref>) reveals the hydrophobic core is largely conserved, with Trp<sup>288</sup>, Trp<sup>290</sup>, and Phe<sup>268</sup> and Phe<sup>276</sup> strictly conserved. Deletions, seen in the more distantly related proteins from <italic>Lytechinus pictus</italic> and <italic>Asterina pectinifera</italic>, are confined solely to loop 1, and it is highly likely that the fold is conserved throughout these species. Other residues strictly conserved are Pro<sup>262</sup>, which ends loop 1, and three lysines as follows: Lys<sup>263</sup> and Lys<sup>267</sup> cluster on the surface of the protein, whereas Lys<sup>248</sup> appears to form a salt bridge with Asp<sup>286</sup> (<xref rid="fig2" ref-type="fig">Fig. 2<italic>C</italic></xref>) and may be structurally important.</p><p>The NPM1 C-terminal domain has no significant sequence similarity to any protein or domain, but a search for structurally similar proteins using the program DALI (<xref ref-type="bibr" rid="ref40">40</xref>) returned several matches, among which the most significant single domain protein was the recently published archaeal ribosomal protein S17e (<xref ref-type="bibr" rid="ref41">41</xref>).</p><p><italic>Effect of the Leukemia Mutations on the Structure of the NPM1 C-terminal Domain</italic>&#x02014;NPMc+ mutations alter the sequence of the C terminus of the third helix in the structure. In the most common mutation, mutant A, the wild-type sequence WQWRKSL is replaced by the sequence CLAVEEVSLRK, whereas in the less common mutant E it is replaced with WQS-LAQVSLRK (<xref rid="fig3" ref-type="fig">Fig. 3<italic>C</italic></xref>). Several of the altered residues are at the interface between helix 3 and helices 2 and 1 and contribute to the hydrophobic core of the domain. In the NPMc+ mutants, these residues are replaced by smaller amino acids, and this would be predicted to greatly destabilize the domain. To test this hypothesis, we used NMR spectroscopy. The one-dimensional <sup>1</sup>H NMR spectra of both mutants A and E show a decrease in dispersion compared with NPM1wt (<xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>), indicative of a loss of tertiary structure. <xref rid="fig3" ref-type="fig">Fig. 3<italic>B</italic></xref> shows the CD spectra of NPM1wt and mutants A and E as a function of temperature. NPM1wt describes a sigmoidal unfolding transition typical of a folded protein, whereas mutant A shows no evidence of any such transition and yields a trace similar to that expected from an unstructured protein. Mutant E shows an intermediate response; there is evidence of a transition, but the protein never appears to fully occupy the folded state of the wild type.</p><p><fig position="float" id="fig2"><label>FIGURE 2.</label><caption><p><bold>Sequence alignment and the positions of structurally and functionally important residues.</bold><italic>A-C,</italic> schematic representations of the C-terminal domain of nucleophosmin colored <italic>blue</italic> to <italic>red</italic> from the N to C terminus with structurally and functionally important residues highlighted as <italic>sticks.</italic> Figure was prepared using the program PyMOL (<xref ref-type="bibr" rid="ref53">53</xref>). <italic>A,</italic> Trp<sup>288</sup> and Trp<sup>290</sup> showing their positions in the core. <italic>B,</italic> Phe<sup>268</sup> and Phe<sup>276</sup>, for comparison with <italic>A. C,</italic> residues Lys<sup>248</sup> and Asp<sup>286</sup> that form a salt bridge and Lys<sup>263</sup> and Lys<sup>267</sup>, which cluster on the surface. <italic>D,</italic> structure-based sequence alignment of the C-terminal domain of nucleophosmin and related proteins. Sequences were aligned using the programs ClustalW (<xref ref-type="bibr" rid="ref54">54</xref>) and Jalview (<xref ref-type="bibr" rid="ref55">55</xref>) and shaded <italic>blue</italic> according to the degree of conservation. Proteins and their NCBI accession numbers are as follows: nucleophosmin 1 from <italic>Homo sapiens</italic> gi:10835063, <italic>Mus musculus</italic> gi:56206422, <italic>Danio rerio</italic> gi:31418910, <italic>Gallus gallus</italic> gi:45383996. NO38 from <italic>Xenopus laevis</italic> gi:64919, Mitotic Apparatus Protein p62 from <italic>L. pictus</italic> gi:1841528 and nucleolar protein from <italic>A. pectinifera</italic> gi:18146874.</p></caption><graphic xlink:href="zbc0330845150002"></graphic></fig></p><p><fig position="float" id="fig3"><label>FIGURE 3.</label><caption><p><bold>Biophysical analysis of nucleophosmin variants.</bold><italic>A,</italic> amide region of one-dimensional <sup>1</sup>H NMR spectra of the C-terminal domains of the nucleophosmin variants: wild-type(<italic>wt</italic>); mutant A (<italic>Mut A</italic>); mutant E(<italic>Mut E</italic>);W288A/W290A (<italic>DW</italic>), and F268A/F276A. All mutants show a decrease in dispersion compared with wild type, indicating that all mutants are unfolded. <italic>B,</italic> traces from thermal melts of nucleophosmin C-terminal domain variants followed by differential absorbance at 222 nm by circular dichroism spectroscopy. The <italic>blue points</italic> correspond to wild type (<italic>wt</italic>), the <italic>green</italic> to Mutant E (<italic>Mut E</italic>), and the <italic>red</italic> to Mutant A (<italic>Mut A</italic>). Wild-type describes a typical two-state sigmoidal transition. Differential scanning calorimetry was used to corroborate this result and agreed within experimental error to a <italic>T<sub>m</sub></italic> of 62 &#x000b0;C and &#x00394;<italic>H</italic><sub>unfolding</sub> of 40 kcal&#x000b7;mol<sup>-1</sup>. Mutant A shows no sign of any transition, whereas mutant E exhibits some degree of transition although appears to never fully occupy the folded state of wild-type NPM1. <italic>C, table</italic> displaying the C-terminal sequences of wild-type NPM1 compared with mutants A and E. All naturally occurring mutations found in AML, including A and E, are because of a frameshift that results in the substitution of the extreme Cterminus (including one or both of the tryptophans Trp<sup>288</sup> and Trp<sup>290</sup>) with aleucine-rich NES. Substituted residues are colored <italic>red</italic> and those forming the NES motif are <italic>underlined</italic>.</p></caption><graphic xlink:href="zbc0330845150003"></graphic></fig></p><p><fig position="float" id="fig4"><label>FIGURE 4.</label><caption><p><bold>Cellular localization of C-terminal domain variants, structural mutants.</bold> NIH-3T3 cells were transfected with eGFP tagged full-length nucleophosmin variants, as indicated. <italic>A,</italic> wild type (<italic>wt</italic>); <italic>B,</italic> mutant A (<italic>Mut A</italic>); <italic>C,</italic> W288A/W290A; <italic>D,</italic> F268A/F276A (<italic>left panel</italic>). Cells were co-stained with anti-fibrillarin antibody to highlight the nucleolus (<italic>middle panel</italic>). As expected, wild-type NPM1 is entirely nucleolar and mutant A is entirely cytoplasmic. Mutant eGPF-NPM1 W288A/W290A is nuclear and exclusive of the nucleolus, as too is mutant eGFP-NPM1 F268A/F276A.</p></caption><graphic xlink:href="zbc0330845150004"></graphic></fig></p><p>These results suggest that the mutations found in AML lead to the destabilization of the C-terminal globular domain of NPM1. Mutant A, which lacks both Trp<sup>288</sup> and Trp<sup>290</sup>, has no residual regular secondary structure. Interestingly, mutant E (in which Trp<sup>288</sup> is retained), although largely destabilized, is clearly not completely unstructured. This mutant may retain some ability to localize NPM1 to the nucleolus, and this could explain why it has a stronger nuclear export signal than mutant A (<xref ref-type="bibr" rid="ref42">42</xref>), which itself is completely unfolded.</p><p><italic>A Folded C-terminal Domain Is Required for Nucleolar Targeting</italic>&#x02014;Expressing NPM1 as an eGFP fusion in mammalian cells allows for the direct observation of its subcellular localization (<xref ref-type="bibr" rid="ref43">43</xref>). In this manner the mutation of Trp<sup>288</sup> and Trp<sup>290</sup> to alanine in NPM1 has been shown to lead to loss of nucleolar localization and the accumulation of the protein in the nucleus (<xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref28">28</xref>). To date it has not been clear how these residues contributed to the direction of NPM1 to the nucleolus. We have shown that Trp<sup>288</sup> and Trp<sup>290</sup> are part of the hydrophobic core of a folded domain (<xref rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>), and it would be expected that their mutation would lead to a loss of structure. Indeed, the NPM1 C-terminal domain with Trp<sup>288</sup> and Trp<sup>290</sup> mutated to alanine lacks any distinct tertiary structure (as judged by one-dimensional <sup>1</sup>H NMR; see <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>) and does not undergo a cooperative unfolding transition when heated (<xref rid="fig3" ref-type="fig">Fig. 3<italic>B</italic></xref>). This would suggest that mutation of these residues prevents nucleolar localization simply by preventing the correct folding of the C-terminal domain of NPM1. To test this hypothesis, we decided to make other mutations in the C-terminal domain that would be expected to disrupt its structure while retaining the tryptophans. To this end we chose to mutate phenylalanines 268 and 276 to alanine (F268A and F276A) as these residues are also strictly conserved, large hydrophobic residues that pack at the interfaces of the helices and make many contacts within the core (<xref rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>, and compared with <xref rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>). As expected the NPM1 domain containing the F268A/F276A mutations lacks any distinct tertiary structure (<xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>). We next examined the effects of these mutations on subcellular localization by transfecting full-length green fluorescent protein-tagged NPM1 F268A/F276A into NIH-3T3 cells. The mutant eGFP-NPM1 F268A/F276A is nuclear and excluded from the nucleolus (<xref rid="fig4" ref-type="fig">Fig. 4</xref>), thus proving that nucleolar localization is a property of the C-terminal domain as a whole.</p><p>It has been reported by Falini <italic>et al.</italic> (<xref ref-type="bibr" rid="ref27">27</xref>) that re-inserting Trp<sup>288</sup> and Trp<sup>290</sup> into mutant A leads to complete relocalization to the nucleolus. We investigated the C terminus of this mutant A C288W/A290W construct and found it to be folded, as judged by CD and NMR. Presumably, refolding the C terminus of mutant A allows it carry on its normal function within the nucleolus while making the nuclear export signal unavailable to the export machinery. Hence, to better distinguish the role of the NES from nucleolar targeting, we added the nuclear export signal from mutant A (LAVEEVSLRK) to the end of wild-type C-terminal domain with a GGS linker and found the full-length construct to be nucleolar. This indicates that a loss of structure and the addition of a nuclear export signal are necessary to cause the aberrant cytoplasmic localization observed in NPMc+ AML.</p><p><italic>Functionally Important Residues in the C-terminal Domain of NPM1</italic>&#x02014;Within the C-terminal domain of NPM1 lysine residues 248, 263, and 267 are strictly conserved and surface-exposed (<xref rid="fig5" ref-type="fig">Fig. 5</xref>), thus indicating their potential as functionally important residues. To examine this, these residues were mutated to alanine, and the effects on domain stability and nucleolar localization were monitored.</p><p>Although Lys<sup>248</sup> is surface-exposed, it appears to form a long range salt bridge with Asp<sup>286</sup>. Indeed the mutation K248A significantly destabilizes the domain and as such leads to Lys<sup>248</sup> being classified as structurally important as opposed to being directly functional (data not shown).</p><p>Lysines 263 and 267 cluster and orientate freely on the surface of the domain (<xref rid="fig5" ref-type="fig">Fig. 5</xref>, and as judged by a lack of side chain nuclear Overhauser effects), and mutation of either Lys<sup>263</sup> or Lys<sup>267</sup>, or both, increases the stability of the domain in line with the previously described effects of removing unpaired surface charges (<xref ref-type="bibr" rid="ref44">44</xref>). Once established as not structurally detrimental, the nucleolar localization of the full-length NPM1 mutants K263A, K267A, and the double mutant K263A/K267A was studied <italic>in vivo</italic>. Mutant K263A was partially delocalized to the nucleoplasm, and K267A and the double mutant were completely delocalized (<xref rid="fig6" ref-type="fig">Fig. 6</xref>).</p><p><fig position="float" id="fig5"><label>FIGURE 5.</label><caption><p><bold>Electrostatic representation of the C-terminal domain showing functionally important residues.</bold> The electrostatic surface potential of the C-terminal domain of NPM1 as calculated by the program APBS (<xref ref-type="bibr" rid="ref56">56</xref>) and colored using a linear color ramp from -20.0 kiloteslas (<italic>red</italic>) to +20.0 (<italic>blue</italic>). Lys<sup>263</sup> and Lys<sup>267</sup> are required for nucleolar localization, but Lys<sup>250</sup> is not (see <xref rid="fig6" ref-type="fig">Fig. 6</xref>). The natural product avrainvillamide bound to Cys<sup>275</sup> and displaced NPM1 from the nucleolus to the nucleoplasm (<xref ref-type="bibr" rid="ref45">45</xref>).</p></caption><graphic xlink:href="zbc0330845150005"></graphic></fig></p><p><fig position="float" id="fig6"><label>FIGURE 6.</label><caption><p><bold>Cellular localization of C-terminal domain mutants, functional mutants.</bold> NIH-3T3 cells were transfected with eGFP tagged full-length nucleophosmin variants, as indicated. <italic>A,</italic> wild type (<italic>wt</italic>); <italic>B,</italic> K250A; <italic>C,</italic> K263A; <italic>D,</italic> K267A; <italic>E,</italic> K263A/K267A (<italic>left panel</italic>). Cells were co-stained with &#x003b1;-fibrillarin antibody to highlight the nucleolus (<italic>middle panel</italic>). Wild-type NPM1 is entirely localized to the nucleolus, and mutant eGPF-NPM1 K250A is broadly similar. Mutant eGPF-NPM1 K263A is largely displaced into the nucleoplasm but displays some residual nucleolar retention. Mutant eGPF-NPM1 267A and the double mutant eGPF-NPM1 K263A/K267A show no residual nucleolar binding and are evenly distributed throughout the nucleoplasm.</p></caption><graphic xlink:href="zbc0330845150006"></graphic></fig></p><p>As a control, the freely orienting surface lysine Lys<sup>250</sup> was also mutated. The C-terminal mutant K250A was, predictably, more stable than the wild-type domain yet had no significant effect on nucleolar localization (<xref rid="fig6" ref-type="fig">Fig. 6</xref>). This important result emphasizes the specific functional requirement of residues Lys<sup>263</sup> and Lys<sup>267</sup> for nucleolar localization over any nonspecific charge effects.</p></sec><sec><title>DISCUSSION</title><p>Nucleophosmin is a member of the nucleoplasmin family of molecular chaperones and shares the N-terminal pentamerization domain and central acidic region characteristic of these proteins. In this study we have shown that NPM1 has an additional folded domain at its C terminus, which is unique to this subfamily. Although nucleoplasmin is found throughout the nucleus, NPM1 is one of the most abundant proteins in the nucleolus, and this C-terminal domain is necessary for its nucleolar localization. How it directs the protein to the nucleolus is not clear. It seems likely that it binds to a protein or nucleic acid ligand that is abundant in the nucleolus, and it is possible that the structural similarity to ribosomal protein S17e is functionally significant.</p><p>The natural product avrainvillamide has been shown to bind to the C-terminal domain of NPM1 via Cys<sup>275</sup> (<xref ref-type="bibr" rid="ref45">45</xref>) and sensitizes cells to apoptosis. It seems likely that avrainvillamide competes with the natural binding partner of this domain. Interestingly, Cys<sup>275</sup> is on the same face as the two lysine residues that we have shown to be important for nucleolar localization (<xref rid="fig5" ref-type="fig">Fig. 5</xref>) suggesting that this region of the domain is involved in ligand binding.</p><p>Ribosome biogenesis is metabolically expensive and a rate-limiting step in cell division and growth. Consequently, ribosomal integrity is closely monitored by a variety of pathways (<xref ref-type="bibr" rid="ref46">46</xref>). Free ribosomal proteins, for example, activate the tumor suppressor p53 by inhibiting its negative regulator MDM2. There is growing evidence that defects in these pathways can lead to disease. Several blood disorders, for example, are caused by mutations in ribosomal proteins or in ribosome assembly factors (<xref ref-type="bibr" rid="ref47">47</xref>-<xref ref-type="bibr" rid="ref51">51</xref>), and mutations that prevent ribosomal protein binding to MDM2 have been reported in human cancers (<xref ref-type="bibr" rid="ref52">52</xref>). These pathways also seem to be disrupted in NPMc+ AML. NPM1 binds to the p19/ARF tumor suppressor and is also regulated by other pathways that control cell growth (<xref ref-type="bibr" rid="ref18">18</xref>-<xref ref-type="bibr" rid="ref24">24</xref>). It seems likely that misdirection of p19<sup>ARF</sup>, or another key regulatory molecule that binds NPM1, to the cytoplasm may play a key role in AML. The results of this study show that the aberrant cytoplasmic accumulation of NPM1 in NPMc+ AML results from both the gain of a nuclear export signal and the disruption of the structure of its C-terminal domain. Molecules that target the C-terminal domain of NPM1 interfere with this mislocalization could therefore have potential applications in leukemia therapy.</p></sec></body><back><ref-list><ref id="ref1"><label>1</label><citation citation-type="journal">Michalik, J., Yeoman, L. C., and Busch, H. (<year>1981</year>) <source>Life Sci.</source><volume>28</volume><fpage>1371</fpage>-1379<pub-id pub-id-type="pmid">7017325</pub-id></citation></ref><ref id="N0x1cc07a0N0x6161b70"><label>2</label><citation citation-type="journal">Spector, D. L., Ochs, R. L., and Busch, H. (<year>1984</year>) <source>Chromosoma (Berl.)</source><volume>90</volume><fpage>139</fpage>-148<pub-id pub-id-type="pmid">6206987</pub-id></citation></ref><ref id="ref3"><label>3</label><citation citation-type="journal">Andersen, J. S., Lam, Y. W., Leung, A. K., Ong, S. E., Lyon, C. E., Lamond, A. I., and Mann, M. (<year>2005</year>) <source>Nature</source><volume>433</volume><fpage>77</fpage>-83<pub-id pub-id-type="pmid">15635413</pub-id></citation></ref><ref id="ref4"><label>4</label><citation citation-type="journal">Tschochner, H., and Hurt, E. (<year>2003</year>) <source>Trends Cell Biol.</source><volume>13</volume><fpage>255</fpage>-263<pub-id pub-id-type="pmid">12742169</pub-id></citation></ref><ref id="ref5"><label>5</label><citation citation-type="journal">Borer, R. A., Lehner, C. F., Eppenberger, H. M., and Nigg, E. A. (<year>1989</year>) <source>Cell</source><volume>56</volume><fpage>379</fpage>-390<pub-id pub-id-type="pmid">2914325</pub-id></citation></ref><ref id="N0x1cc07a0N0x1e90eb8"><label>6</label><citation citation-type="journal">Yun, J. P., Chew, E. C., Liew, C. T., Chan, J. Y., Jin, M. L., Ding, M. X., Fai, Y. H., Li, H. K., Liang, X. M., and Wu, Q. L. (<year>2003</year>) <source>J. Cell Biochem.</source><volume>90</volume><fpage>1140</fpage>-1148<pub-id pub-id-type="pmid">14635188</pub-id></citation></ref><ref id="ref7"><label>7</label><citation citation-type="journal">Leung, A. K., Gerlich, D., Miller, G., Lyon, C., Lam, Y. W., Lleres, D., Daigle, N., Zomerdijk, J., Ellenberg, J., and Lamond, A. I. (<year>2004</year>) <source>J. Cell Biol.</source><volume>166</volume><fpage>787</fpage>-800<pub-id pub-id-type="pmid">15353547</pub-id></citation></ref><ref id="ref8"><label>8</label><citation citation-type="journal">Hingorani, K., Szebeni, A., and Olson, M. O. (<year>2000</year>) <source>J. Biol. Chem.</source><volume>275</volume><fpage>24451</fpage>-24457<pub-id pub-id-type="pmid">10829026</pub-id></citation></ref><ref id="N0x1cc07a0N0x1e915c0"><label>9</label><citation citation-type="journal">Okuwaki, M., Tsujimoto, M., and Nagata, K. (<year>2002</year>) <source>Mol. Biol. Cell</source><volume>13</volume><fpage>2016</fpage>-2030<pub-id pub-id-type="pmid">12058066</pub-id></citation></ref><ref id="N0x1cc07a0N0x1e91848"><label>10</label><citation citation-type="journal">Szebeni, A., and Olson, M. O. (<year>1999</year>) <source>Protein Sci.</source><volume>8</volume><fpage>905</fpage>-912<pub-id pub-id-type="pmid">10211837</pub-id></citation></ref><ref id="ref11"><label>11</label><citation citation-type="journal">Wang, D., Baumann, A., Szebeni, A., and Olson, M. O. (<year>1994</year>) <source>J. Biol. Chem.</source><volume>269</volume><fpage>30994</fpage>-30998<pub-id pub-id-type="pmid">7527039</pub-id></citation></ref><ref id="ref12"><label>12</label><citation citation-type="journal">Grisendi, S., Bernardi, R., Rossi, M., Cheng, K., Khandker, L., Manova, K., and Pandolfi, P. P. (<year>2005</year>) <source>Nature</source><volume>437</volume><fpage>147</fpage>-153<pub-id pub-id-type="pmid">16007073</pub-id></citation></ref><ref id="ref13"><label>13</label><citation citation-type="journal">Olson, M. O., Wallace, M. O., Herrera, A. H., Marshall-Carlson, L., and Hunt, R. C. (<year>1986</year>) <source>Biochemistry</source><volume>25</volume><fpage>484</fpage>-491<pub-id pub-id-type="pmid">3955008</pub-id></citation></ref><ref id="N0x1cc07a0N0x1e92190"><label>14</label><citation citation-type="journal">Herrera, J. E., Savkur, R., and Olson, M. O. (<year>1995</year>) <source>Nucleic Acids Res.</source><volume>23</volume><fpage>3974</fpage>-3979<pub-id pub-id-type="pmid">7479045</pub-id></citation></ref><ref id="N0x1cc07a0N0x1e92418"><label>15</label><citation citation-type="journal">Savkur, R. S., and Olson, M. O. (<year>1998</year>) <source>Nucleic Acids Res.</source><volume>26</volume><fpage>4508</fpage>-4515<pub-id pub-id-type="pmid">9742256</pub-id></citation></ref><ref id="ref16"><label>16</label><citation citation-type="journal">Yu, Y., Maggi, L. B., Jr., Brady, S. N., Apicelli, A. J., Dai, M. S., Lu, H., and Weber, J. D. (<year>2006</year>) <source>Mol. Cell. Biol.</source><volume>26</volume><fpage>3798</fpage>-3809<pub-id pub-id-type="pmid">16648475</pub-id></citation></ref><ref id="ref17"><label>17</label><citation citation-type="journal">Grisendi, S., Mecucci, C., Falini, B., and Pandolfi, P. P. (<year>2006</year>) <source>Nat. Rev. Cancer</source><volume>6</volume><fpage>493</fpage>-505<pub-id pub-id-type="pmid">16794633</pub-id></citation></ref><ref id="ref18"><label>18</label><citation citation-type="journal">den Besten, W., Kuo, M. L., Williams, R. T., and Sherr, C. J. (<year>2005</year>) <source>Cell Cycle</source><volume>4</volume><fpage>1593</fpage>-1598<pub-id pub-id-type="pmid">16205118</pub-id></citation></ref><ref id="N0x1cc07a0N0x1e94700"><label>19</label><citation citation-type="journal">Brady, S. N., Yu, Y., Maggi, L. B., Jr., and Weber, J. D. (<year>2004</year>) <source>Mol. Cell Biol.</source><volume>24</volume><fpage>9327</fpage>-9338<pub-id pub-id-type="pmid">15485902</pub-id></citation></ref><ref id="N0x1cc07a0N0x1e94988"><label>20</label><citation citation-type="journal">Bertwistle, D., Sugimoto, M., and Sherr, C. J. (<year>2004</year>) <source>Mol. Cell. Biol.</source><volume>24</volume><fpage>985</fpage>-996<pub-id pub-id-type="pmid">14729947</pub-id></citation></ref><ref id="N0x1cc07a0N0x1e94c10"><label>21</label><citation citation-type="journal">Colombo, E., Marine, J. C., Danovi, D., Falini, B., and Pelicci, P. G. (<year>2002</year>) <source>Nat. Cell Biol.</source><volume>4</volume><fpage>529</fpage>-533<pub-id pub-id-type="pmid">12080348</pub-id></citation></ref><ref id="ref22"><label>22</label><citation citation-type="journal">Itahana, K., Bhat, K. P., Jin, A., Itahana, Y., Hawke, D., Kobayashi, R., and Zhang, Y. (<year>2003</year>) <source>Mol. Cell</source><volume>12</volume><fpage>1151</fpage>-1164<pub-id pub-id-type="pmid">14636574</pub-id></citation></ref><ref id="ref23"><label>23</label><citation citation-type="journal">Boon, K., Caron, H. N., van Asperen, R., Valentijn, L., Hermus, M. C., van Sluis, P., Roobeek, I., Weis, I., Voute, P. A., Schwab, M., and Versteeg, R. (<year>2001</year>) <source>EMBO J.</source><volume>20</volume><fpage>1383</fpage>-1393<pub-id pub-id-type="pmid">11250904</pub-id></citation></ref><ref id="ref24"><label>24</label><citation citation-type="journal">Zeller, K. I., Haggerty, T. J., Barrett, J. F., Guo, Q., Wonsey, D. R., and Dang, C. V. (<year>2001</year>) <source>J. Biol. Chem.</source><volume>276</volume><fpage>48285</fpage>-48291<pub-id pub-id-type="pmid">11604407</pub-id></citation></ref><ref id="ref25"><label>25</label><citation citation-type="journal">Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P. G., and Martelli, M. F. (<year>2005</year>) <source>N. Engl. J. Med.</source><volume>352</volume><fpage>254</fpage>-266<pub-id pub-id-type="pmid">15659725</pub-id></citation></ref><ref id="ref26"><label>26</label><citation citation-type="journal">Nakagawa, M., Kameoka, Y., and Suzuki, R. (<year>2005</year>) <source>N. Engl. J. Med.</source><volume>352</volume><fpage>1819</fpage>-1820</citation></ref><ref id="ref27"><label>27</label><citation citation-type="journal">Falini, B., Bolli, N., Shan, J., Martelli, M. P., Liso, A., Pucciarini, A., Bigerna, B., Pasqualucci, L., Mannucci, R., Rosati, R., Gorello, P., Diverio, D., Roti, G., Tiacci, E., Cazzaniga, G., Biondi, A., Schnittger, S., Haferlach, T., Hiddemann, W., Martelli, M. F., Gu, W., Mecucci, C., and Nicoletti, I. (<year>2006</year>) <source>Blood</source><volume>107</volume><fpage>4514</fpage>-4523<pub-id pub-id-type="pmid">16455950</pub-id></citation></ref><ref id="ref28"><label>28</label><citation citation-type="journal">Nishimura, Y., Ohkubo, T., Furuichi, Y., and Umekawa, H. (<year>2002</year>) <source>Biosci. Biotechnol. Biochem.</source><volume>66</volume><fpage>2239</fpage>-2242<pub-id pub-id-type="pmid">12450141</pub-id></citation></ref><ref id="ref29"><label>29</label><citation citation-type="journal">Gill, S. C., and von Hippel, P. H. (<year>1989</year>) <source>Anal. Biochem.</source><volume>182</volume><fpage>319</fpage>-326<pub-id pub-id-type="pmid">2610349</pub-id></citation></ref><ref id="ref30"><label>30</label><citation citation-type="journal">Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. (<year>1995</year>) <source>Protein Sci.</source><volume>4</volume><fpage>2411</fpage>-2423<pub-id pub-id-type="pmid">8563639</pub-id></citation></ref><ref id="ref31"><label>31</label><citation citation-type="journal">Neri, D., Szyperski, T., Otting, G., Senn, H., and Wuthrich, K. (<year>1989</year>) <source>Biochemistry</source><volume>28</volume><fpage>7510</fpage>-7516<pub-id pub-id-type="pmid">2692701</pub-id></citation></ref><ref id="ref32"><label>32</label><citation citation-type="other">Goddard, T. D., and Kneller, D. G. (<year>2007</year>) <source>SPARKY 3</source>, University of California, San Francisco</citation></ref><ref id="ref33"><label>33</label><citation citation-type="journal">Mori, S., Abeygunawardana, C., Johnson, M. O., and van Zijl, P. C. (<year>1995</year>) <source>J. Magn. Reson.</source><volume>108</volume><fpage>94</fpage>-98</citation></ref><ref id="ref34"><label>34</label><citation citation-type="journal">Cornilescu, G., Delaglio, F., and Bax, A. (<year>1999</year>) <source>J. Biomol. NMR</source><volume>13</volume><fpage>289</fpage>-302<pub-id pub-id-type="pmid">10212987</pub-id></citation></ref><ref id="ref35"><label>35</label><citation citation-type="journal">Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (<year>1998</year>) <source>Acta Crystallogr. Sect. D Biol. Crystallogr.</source><volume>54</volume><fpage>905</fpage>-921<pub-id pub-id-type="pmid">9757107</pub-id></citation></ref><ref id="ref36"><label>36</label><citation citation-type="other">Schmid, F. X. (<year>1989</year>) <source>Spectral Methods of Characterizing Protein Conformation and Conformational Changes</source>, (Creighton, T. E. ed) pp. <fpage>251</fpage>-285, IRL Press at Oxford University Press, Oxford, UK</citation></ref><ref id="ref37"><label>37</label><citation citation-type="journal">Cuff, J. A., Clamp, M. E., Siddiqui, A. S., Finlay, M., and Barton, G. J. (<year>1998</year>) <source>Bioinformatics (Oxf.)</source><volume>14</volume><fpage>892</fpage>-893</citation></ref><ref id="ref38"><label>38</label><citation citation-type="other">W&#x000fc;thrich, K. (<year>1986</year>) <source>NMR of Proteins and Nucleic Acid</source>, John Wiley &#x00026; Sons, Inc., New York</citation></ref><ref id="ref39"><label>39</label><citation citation-type="journal">Bax, A. (<year>1994</year>) <source>Curr. Opin. Struct. Biol.</source><volume>4</volume><fpage>738</fpage>-744</citation></ref><ref id="ref40"><label>40</label><citation citation-type="journal">Holm, L., and Sander, C. (<year>1995</year>) <source>Trends Biochem. Sci.</source><volume>20</volume><fpage>478</fpage>-480<pub-id pub-id-type="pmid">8578593</pub-id></citation></ref><ref id="ref41"><label>41</label><citation citation-type="journal">Wu, B., Yee, A., Huang, Y. J., Ramelot, T. A., Cort, J. R., Semesi, A., Jung, J. W., Lee, W., Montelione, G. T., Kennedy, M. A., and Arrowsmith, C. H. (<year>2008</year>) <source>Protein Sci.</source>, <volume>17</volume><fpage>583</fpage>-588<pub-id pub-id-type="pmid">18218711</pub-id></citation></ref><ref id="ref42"><label>42</label><citation citation-type="journal">Bolli, N., Nicoletti, I., De Marco, M. F., Bigerna, B., Pucciarini, A., Mannucci, R., Martelli, M. P., Liso, A., Mecucci, C., Fabbiano, F., Martelli, M. F., Henderson, B. R., and Falini, B. (<year>2007</year>) <source>Cancer Res.</source><volume>67</volume><fpage>6230</fpage>-6237<pub-id pub-id-type="pmid">17616680</pub-id></citation></ref><ref id="ref43"><label>43</label><citation citation-type="journal">Dundr, M., Misteli, T., and Olson, M. O. (<year>2000</year>) <source>J. Cell Biol.</source><volume>150</volume><fpage>433</fpage>-446<pub-id pub-id-type="pmid">10931858</pub-id></citation></ref><ref id="ref44"><label>44</label><citation citation-type="journal">Serrano, L., Horovitz, A., Avron, B., Bycroft, M., and Fersht, A. R. (<year>1990</year>) <source>Biochemistry</source><volume>29</volume><fpage>9343</fpage>-9352<pub-id pub-id-type="pmid">2248951</pub-id></citation></ref><ref id="ref45"><label>45</label><citation citation-type="journal">Wulff, J. E., Siegrist, R., and Myers, A. G. (<year>2007</year>) <source>J. Am. Chem. Soc.</source><volume>129</volume><fpage>14444</fpage>-14451<pub-id pub-id-type="pmid">17958425</pub-id></citation></ref><ref id="ref46"><label>46</label><citation citation-type="journal">Ruggero, D., and Pandolfi, P. P. (<year>2003</year>) <source>Nat. Rev. Cancer</source><volume>3</volume><fpage>179</fpage>-192<pub-id pub-id-type="pmid">12612653</pub-id></citation></ref><ref id="ref47"><label>47</label><citation citation-type="journal">Cmejla, R., Cmejlova, J., Handrkova, H., Petrak, J., and Pospisilova, D. (<year>2007</year>) <source>Hum. Mutat.</source><volume>28</volume><fpage>1178</fpage>-1182<pub-id pub-id-type="pmid">17647292</pub-id></citation></ref><ref id="N0x1cc07a0N0x477c618"><label>48</label><citation citation-type="journal">Draptchinskaia, N., Gustavsson, P., Andersson, B., Pettersson, M., Willig, T. N., Dianzani, I., Ball, S., Tchernia, G., Klar, J., Matsson, H., Tentler, D., Mohandas, N., Carlsson, B., and Dahl, N. (<year>1999</year>) <source>Nat. Genet.</source><volume>21</volume><fpage>169</fpage>-175<pub-id pub-id-type="pmid">9988267</pub-id></citation></ref><ref id="N0x1cc07a0N0x477c8a0"><label>49</label><citation citation-type="journal">Ebert, B. L., Pretz, J., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E., Ellis, S. R., and Golub, T. R. (<year>2008</year>) <source>Nature</source><volume>451</volume><fpage>335</fpage>-339<pub-id pub-id-type="pmid">18202658</pub-id></citation></ref><ref id="N0x1cc07a0N0x477cb28"><label>50</label><citation citation-type="journal">Gazda, H. T., Grabowska, A., Merida-Long, L. B., Latawiec, E., Schneider, H. E., Lipton, J. M., Vlachos, A., Atsidaftos, E., Ball, S. E., Orfali, K. A., Niewiadomska, E., Da Costa, L., Tchernia, G., Niemeyer, C., Meerpohl, J. J., Stahl, J., Schratt, G., Glader, B., Backer, K., Wong, C., Nathan, D. G., Beggs, A. H., and Sieff, C. A. (<year>2006</year>) <source>Am. J. Hum. Genet.</source><volume>79</volume><fpage>1110</fpage>-1118<pub-id pub-id-type="pmid">17186470</pub-id></citation></ref><ref id="ref51"><label>51</label><citation citation-type="journal">Menne, T. F., Goyenechea, B., Sanchez-Puig, N., Wong, C. C., Tonkin, L. M., Ancliff, P. J., Brost, R. L., Costanzo, M., Boone, C., and Warren, A. J. (<year>2007</year>) <source>Nat. Genet.</source><volume>39</volume><fpage>486</fpage>-495<pub-id pub-id-type="pmid">17353896</pub-id></citation></ref><ref id="ref52"><label>52</label><citation citation-type="journal">Lindstrom, M. S., Jin, A., Deisenroth, C., White Wolf, G., and Zhang, Y. (<year>2007</year>) <source>Mol. Cell. Biol.</source><volume>27</volume><fpage>1056</fpage>-1068<pub-id pub-id-type="pmid">17116689</pub-id></citation></ref><ref id="ref53"><label>53</label><citation citation-type="other">DeLano, W. L. (<year>2002</year>) <source>The PyMOL Molecular Graphics System</source>, DeLano Scientific, San Carlos, CA</citation></ref><ref id="ref54"><label>54</label><citation citation-type="journal">Chenna, R., Sugawara, H., Koike, T., Lopez, R., Gibson, T. J., Higgins, D. G., and Thompson, J. D. (<year>2003</year>) <source>Nucleic Acids Res.</source><volume>31</volume><fpage>3497</fpage>-3500<pub-id pub-id-type="pmid">12824352</pub-id></citation></ref><ref id="ref55"><label>55</label><citation citation-type="journal">Clamp, M., Cuff, J., Searle, S. M., and Barton, G. J. (<year>2004</year>) <source>Bioinformatics (Oxf.)</source><volume>20</volume><fpage>426</fpage>-427</citation></ref><ref id="ref56"><label>56</label><citation citation-type="journal">Baker, N. A., Sept, D., Joseph, S., Holst, M. J., and McCammon, J. A. (<year>2001</year>) <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>98</volume><fpage>10037</fpage>-10041<pub-id pub-id-type="pmid">11517324</pub-id></citation></ref></ref-list><fn-group><fn id="fn2"><label>2</label><p>The abbreviations used are: AML, acute myeloid leukemia; NES, nuclear export signal; NOESY, nuclear Overhauser effect spectroscopy; eGFP, enhanced green fluorescent protein; MES, 4-morpholineethanesulfonic acid; PBS, phosphate-buffered saline; TOCSY, total correlation spectroscopy; HSQC, heteronuclear single quantum correlation spectroscopy; MOPS, 4-morpholinepropanesulfonic acid.</p></fn></fn-group></back></article> 